1Olefsky JM, Saltiel AR. PPAR gamma and the treatment of insulin resistance[J]. Trends Endocrinol Metab, 2000,11:362.
2Weston WM, Heise MA, Porter LE, et al. Rosiglitazone-mediated reductions in urinary albumin excretion are associated with changes in ambulatory blood pressure in type 2 diabetes patients[J]. Diabetes, 2001,50 (Suppl 2):A134.
3Sharma K, McGowan TA. TGF-beta in diabetic kidney disease: role of novel signaling pathways[J]. Cytokine Growth Factor Rev, 2000,11:115.
4Nicholas SB, Kawano Y, Wakino S, et al. Expression and function of peroxisome proliferator-activated receptor-gammain mesangial cells[J]. Hypertension,2001,37:722.
5Isshiki K, Haneda M, Koya D, et al. Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats[J].Diabetes, 2000,49:1022.
6Nakamura T, Ushiyama C, Shimada N, et al. Comparative effects of pioglitazone, glibenclamide, and voglibose on urinaryendothelin-1 and albumin excretion in diabetes patients[J]. J Diabetes Complications,2000, 14:250.
7Reilly CM, Oates JC, Sudian J, et al. Prostaglandin J(2) inhibition of mesangial cell iNOS expression[J]. Clin Immunol, 2001,98:337.
8Ma LJ, Marcantoni C, Linton MF, et al. Peroxisome proliferator-activated receptor-gamma agonist troglitazoneprotects against nondiabetic glomerulosclerosis in rats[J]. Kidney Int,2001,59:1899.
9EL-Jack AK, Hamm JK,Pilch PF,et al. Reconstitution of insulin-sensitive glucose transport in fibroblasts requires expression of both PPARg and C/EBPa[J]. J Biol Chem,1999,274(12):7946.
10Sato K, Sugawara A, Kudo M,et al. Expression of peroxisome proliferator-activated receptor isoform proteins in the rat kidney[J]. Hypertens Res,2004,27(6):417.
